BAM
CCXI

Blueshift Asset Management’s ChemoCentryx, Inc. CCXI Stock Holding History

Blueshift Asset Management’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-51,600
Closed -$1.29M – 1088
2022
Q1 		$1.29M Buy
+51,600
New +$1.45M 0.12% 222

Other funds holding CCXI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Blueshift Asset Management's CCXI Position: Q2 2022 in Review

Blueshift Asset Management sold out of ChemoCentryx, Inc. (CCXI) in Q2 2022, closing a stake of 51,600 shares — an estimated $1.29M sold.

Blueshift Asset Management first reported a position in CCXI in Q1 2022 and held it in 1 quarter. The position peaked at $1.29M in Q1 2022. 182 funds tracked by Wall St. Rank hold CCXI as of Q2 2022.

  • Blueshift Asset Management reported no remaining ChemoCentryx, Inc. position as of Q2 2022 after selling out during the quarter.
  • Blueshift Asset Management sold 51,600 ChemoCentryx, Inc. shares in Q2 2022, an estimated $1.29M.
  • Blueshift Asset Management first reported a position in ChemoCentryx, Inc. in Q1 2022 and held it in 1 quarter.
  • Blueshift Asset Management's ChemoCentryx, Inc. position peaked at $1.29M in Q1 2022.
  • 182 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q2 2022.

Based on Blueshift Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.